A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Bendamustine/Rituximab (BR) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose
approximately 30 months
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
GO28440
NCT01671904
May 2013
September 2015
Name | Location |
---|---|
Fountain Valley, California 92708 | |
Seattle, Washington 98195 | |
Washington, District of Columbia |